REFERENCES
1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229-63.
2. Rajaram R, Huang Q, Li RZ, et al. Recurrence-free survival in patients with surgically resected non-small cell lung cancer. Chest. 2024;165:1260-70.
3. Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res. 2014;3:242-9.
4. Fonseca NM, Maurice-Dror C, Herberts C, et al. Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer. Nat Commun. 2024;15:1828.
5. Garcia-Murillas I, Chopra N, Comino-Méndez I, et al. Assessment of molecular relapse detection in early-stage breast cancer. JAMA Oncol. 2019;5:1473-8.
6. Parikh AR, Van Seventer EE, Siravegna G, et al. Minimal Residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. Clin Cancer Res. 2021;27:5586-94.
7. Sfakianos JP, Basu A, Laliotis G, et al. Association of tumor-informed circulating tumor DNA detectability before and after radical cystectomy with disease-free survival in patients with bladder cancer. Eur Urol Oncol. 2025;8:306-14.
8. Kurma K, Eslami-S Z, Alix-Panabières C, Cayrefourcq L. Liquid biopsy: paving a new avenue for cancer research. Cell Adh Migr. 2024;18:1-26.
9. Gale D, Heider K, Ruiz-Valdepenas A, et al. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer. Ann Oncol. 2022;33:500-10.
10. Qiu B, Guo W, Zhang F, et al. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. Nat Commun. 2021;12:6770.
11. Abbosh C, Frankell AM, Harrison T, et al. ; TRACERx Consortium. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature. 2023;616:553-62.
12. Herbst RS, John T, Grohé C, et al. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer. Nat Med. 2025;31:1958-68.
13. Abbosh C, Birkbak NJ, Wilson GA, et al. ; PEACE consortium. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545:446-51.
14. Hong TH, Hwang S, Dasgupta A, et al. Clinical utility of tumor-naïve presurgical circulating tumor DNA detection in early-stage NSCLC. J Thorac Oncol. 2024;19:1512-24.
15. Gassa A, Fassunke J, Schueten S, et al. Detection of circulating tumor DNA by digital droplet PCR in resectable lung cancer as a predictive tool for recurrence. Lung Cancer. 2021;151:91-6.
16. Chaudhuri AA, Chabon JJ, Lovejoy AF, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 2017;7:1394-403.
17. Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34:547-55.
18. Kurtz DM, Soo J, Co Ting Keh L, et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol. 2021;39:1537-47.
19. Normanno N, Morabito A, Rachiglio AM, et al. Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation? Nat Rev Clin Oncol. 2025;22:215-31.
20. Peng M, Huang Q, Yin W, et al. Circulating Tumor DNA as a prognostic biomarker in localized non-small cell lung cancer. Front Oncol. 2020;10:561598.
21. Waldeck S, Mitschke J, Wiesemann S, et al. Early assessment of circulating tumor DNA after curative‐intent resection predicts tumor recurrence in early-stage and locally advanced non‐small‐cell lung cancer. Mol Oncol. 2021;16:527-37.
22. Zhang JT, Liu SY, Gao W, et al. Longitudinal undetectable molecular residual disease defines potentially cured population in localized non-small cell lung cancer. Cancer Discov. 2022;12:1690-701.
23. Xia L, Mei J, Kang R, et al. Perioperative ctDNA-based molecular residual disease detection for non-small cell lung cancer: a prospective multicenter cohort study (LUNGCA-1). Clin Cancer Res. 2022;28:3308-17.
24. Chen K, Zhao H, Shi Y, et al. Perioperative dynamic changes in circulating tumor DNA in patients with lung cancer (DYNAMIC). Clin Cancer Res. 2019;25:7058-67.
25. Felip E, Srivastava M, Reck M, et al. 1O IMpower010: ctDNA status in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC). Immuno-Oncol. Technol. 2022;16:100106.
26. Provencio M, Serna-Blasco R, Nadal E, et al. Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non-small-cell lung cancer (NADIM phase II trial). J Clin Oncol. 2022;40:2924-33.
27. Reck M, Gale D, Harpole D, et al. LBA59 Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial. Ann Oncol. 2023;34:S1300.
28. Reck M, Gale D, Zhu Z, et al. LBA49 Associations of ctDNA clearance (CL) during neoadjuvant Tx with pathological response and event-free survival (EFS) in pts with resectable NSCLC (R-NSCLC): expanded analyses from AEGEAN. Ann Oncol. 2024;35:S1239.
29. Yue D, Liu W, Chen C, et al. Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients. Transl Lung Cancer Res. 2022;11:263-76.
30. Costa J, Membrino A, Zanchetta C, et al. The role of ctDNA in the management of non-small-cell lung cancer in the AI and NGS era. Int J Mol Sci. 2024;25:13669.
31. Boukouris AE, Michaelidou K, Joosse SA, et al. A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer. NPJ Precis Oncol. 2025;9:178.
32. Zhong R, Gao R, Fu W, et al. Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis. BMC Med. 2023;21:180.
33. Pellini B, Chaudhuri AA. Circulating tumor DNA minimal residual disease detection of non-small-cell lung cancer treated with curative intent. J Clin Oncol. 2022;40:567-75.
34. Yaung SJ, Fuhlbrück F, Peterson M, et al. Clonal hematopoiesis in late-stage non-small-cell lung cancer and its impact on targeted panel next-generation sequencing. JCO Precis Oncol. 2020:1271-9.
35. Assaf ZJF, Zou W, Fine AD, et al. A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. Nat Med. 2023;29:859-68.
36. Fairchild L, Whalen J, D’Aco K, et al. Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing. Sci Transl Med. 2023;15:eabm8729.
37. Bestvina CM, Garassino MC, Neal JW, Wakelee HA, Diehn M, Vokes EE. Early-stage lung cancer: using circulating tumor DNA to get personal. J Clin Oncol. 2023;41:4093-6.
38. Olmedillas-López S, García-Arranz M, García-Olmo D. Current and emerging applications of droplet digital PCR in oncology. Mol Diagn Ther. 2017;21:493-510.
39. Wu LR, Chen SX, Wu Y, Patel AA, Zhang DY. Multiplexed enrichment of rare DNA variants via sequence-selective and temperature-robust amplification. Nat Biomed Eng. 2017;1:714-23.
40. Cascone T, Awad MM, Spicer JD, et al. Perioperative nivolumab in resectable lung cancer. N Engl J Med. 2024:390:1756-69.
41. Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973-85.
42. Forde PM, Spicer JD, Provencio M, et al. Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer. N Engl J Med. 2025;393:741-52.
43. Deveson IW, Gong B, Lai K, et al. ; SEQC2 Oncopanel Sequencing Working Group. Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology. Nat Biotechnol. 2021;39:1115-28.
44. Thalambedu N, Balla M, Sivasubramanian BP, et al. Integrating artificial intelligence with circulating tumor DNA for non-small cell lung cancer: opportunities, challenges, and future directions. Front Med. 2025;12:1612376.
45. Bahado-Singh R, Vlachos KT, Aydas B, Gordevicius J, Radhakrishna U, Vishweswaraiah S. Precision oncology: artificial intelligence and DNA methylation analysis of circulating cell-free DNA for lung cancer detection. Front Oncol. 2022;12:790645.
46. Kim M, Park J, Seonghee Oh , et al. Deep learning model integrating cfDNA methylation and fragment size profiles for lung cancer diagnosis. Sci Rep. 2024;14:14797.
47. Widman AJ, Shah M, Frydendahl A, et al. Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment. Nat Med. 2024;30:1655-66.
48. Zviran A, Schulman RC, Shah M, et al. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat Med. 2020;26:1114-24.
49. Wang S, Xia Z, You J, et al. Enhanced detection of landmark minimal residual disease in lung cancer using cell-free DNA fragmentomics. Cancer Res Commun. 2023;3:933-42.
50. Zhu G, Rahman CR, Getty V, et al. A deep-learning model for quantifying circulating tumour DNA from the density distribution of DNA-fragment lengths. Nat Biomed Eng. 2025;9:307-19.
51. Razavi P, Li BT, Brown DN, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med. 2019;25:1928-37.
52. Wang Y, Xiang YB, Chen XW, et al. PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer. Mil Med Res. 2026;12:94.
53. Zhang JT, Chen KZ, Gao X, et al. LAMPAD: an integrated circulating tumor DNA-based model for predicting potential cure in patients with resected NSCLC. J Thorac Oncol. 2026:103729.
54. Yuan M, Lin X, Ding H, Qu S, Yang Y, Steven Xu X. Treatment-agnostic joint modeling of longitudinal circulating tumor dna predicts survival across first-line regimens in metastatic non-squamous NSCLC. Eur J Pharm Sci. 2025;214:107275.
55. Lu D, Lin N, Li S, et al. Predictive effectiveness of circulating tumor DNA in recurrent early-stage non-small cell lung cancer: an updated meta-analysis. JCO Precis Oncol. 2025;9:e2500489.
56. Schuurbiers MMF, Smith CG, Hartemink KJ, et al. ; the LEMA Study Group and the LUCID Study Group. Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: a retrospective validation study. PLoS Med. 2025;22:e1004574.
57. Abbosh C, Birkbak NJ, Swanton C. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection. Nat Rev Clin Oncol. 2018;15:577-86.
58. Hu Y, Ulrich BC, Supplee J, et al. False-positive plasma genotyping due to clonal hematopoiesis. Clin Cancer Res. 2018;24:4437-43.
59. Coombs CC, Zehir A, Devlin SM, et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell. 2017;21:374-82.e4.
60. Yun JK, Kim S, An H, et al. Pre-operative clonal hematopoiesis is related to adverse outcome in lung cancer after adjuvant therapy. Genome Med. 2023;15:111.
61. Leal A, van Grieken NCT, Palsgrove DN, et al. White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nat Commun. 2020;11:525.
62. Arango-Argoty G, Haghighi M, Sun GJ, et al. An artificial intelligence-based model for prediction of clonal hematopoiesis variants in cell-free DNA samples. NPJ Precis Oncol. 2025;9:147.
63. Palizban F, Sarbishegi M, Kavousi K, Mehrmohamadi M. Predicting somatic mutation origins in cell-free DNA by semi-supervised GAN models. Heliyon. 2024;10:e39379.
64. van der Pol Y, Moldovan N, Verkuijlen S, et al. The effect of preanalytical and physiological variables on cell-free DNA fragmentation. Clin Chem. 2022;68:803-13.
65. Hu X, Zhang H, Wang Y, et al. Effects of blood-processing protocols on cell-free DNA fragmentomics in plasma: comparisons of one- and two-step centrifugations. Clin Chim Acta. 2024;560:119729.
66. Wang H, Mennea PD, Chan YKE, et al. A standardized framework for robust fragmentomic feature extraction from cell-free DNA sequencing data. Genome Biol. 2025;26:141.
67. van Calster B, Steyerberg EW, Wynants L, van Smeden M. There is no such thing as a validated prediction model. BMC Med. 2023;21:70.
68. Su S, Xuan Y, Fan X, et al. Testing the generalizability of cfDNA fragmentomic features across different studies for cancer early detection. Genomics. 2023;115:110662.
69. Debray TPA, Collins GS, Riley RD, et al. Transparent reporting of multivariable prediction models developed or validated using clustered data: TRIPOD-cluster checklist. BMJ. 2023;380:e071018.
70. Collins GS, Moons KGM, Dhiman P, et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378.
71. Mathios D, Johansen JS, Cristiano S, et al. Detection and characterization of lung cancer using cell-free DNA fragmentomes. Nat Commun. 2021;12:5060.
72. Mazzone PJ, Bach PB, Carey J, et al. Clinical validation of a cell-free DNA fragmentome assay for augmentation of lung cancer early detection. Cancer Discov. 2024;14:2224-42.
73. van ’t Erve I, Alipanahi B, Lumbard K, et al. Cancer treatment monitoring using cell-free DNA fragmentomes. Nat Commun. 2024;15:8801.
74. Riley RD, Archer L, Snell KIE, et al. Evaluation of clinical prediction models (part 2): how to undertake an external validation study. BMJ. 2024;384:e074820.
75. Kobayashi S, Nakamura Y, Hashimoto T, et al. Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing. Int J Clin Oncol. 2025;30:605-54.
76. Sato Y. Liquid biopsy for minimal residual disease and monitoring in early-stage non-small cell lung cancer: current clinical utility and implementation challenges. Explor Med. 2025;6:1001349.
77. Denis MG. Molecular minimal residual disease in resected non-small cell lung cancer: “flattening the curve”. Transl Lung Cancer Res. 2025;14:4180-3.
78. Verzè M, Pluchino M, Leonetti A, et al. Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review. Transl Lung Cancer Res. 2022;11:2588-600.
79. Shi Y, Chen R, Xiong Y, et al. MRD status combined with TNM staging optimizes postoperative prognostic stratification in non-small cell lung cancer: a meta-analysis and systematic review. Lung Cancer. 2025;206:108634.
80. Ohara S, Suda K, Sudhaman S, et al. Clinical significance of perioperative minimal residual disease detected by circulating tumor DNA in patients with lung cancer with a long follow-up data: an exploratory study. JTO Clin Res Rep. 2025;6:100762.
